A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer

Pier Francesco Ferrucci, C. Rabascio, F. Gigli, C. Corsini, G. Giordano, F. Bertolini, G. Martinelli

Research output: Contribution to journalArticle

Abstract

The incidence and prognostic relevance of bone marrow (BM) and leukapheresis (PBPC) tumor cell contamination (TCC) in breast cancer patients is still to be circumstantiated. We developed a new comprehensive gene expression panel to study cytokeratins (CK), maspin (MAS) and mammaglobin (MAM) as possible predictors of prognosis. Forty-eight patients undergoing high dose chemotherapy (HDCT) and PBPC support were enrolled and analyzed for TCC on 116 PBPC apheresis and 96 BM obtained at basal conditions. All of the patients were evaluated by reverse transcriptase nested PCR (RT-PCR) for MAM and MAS gene expression and by immunocytochemistry (ICC) and nested RT-PCR to evaluate CK expression. PBPC and BM frequency of CK-positive (+) cells was 12-13% by ICC and 71-73% by RT-PCR respectively. Sixty-seven percent of CK ICC + samples were MAM RT-PCR + and 89% of them were MAS RT-PCR +. PBPC and BM frequency of MAM + cells was 21% and 31% respectively, while for MAS + cells it was 48% and 52% respectively by RT-PCR. After 71 mo median FU, 16 patients (33%) relapsed and 14 (88%) had BM/PBPC TCC. No marker had an impact on overall survival (OS) but MAS expression on BM and MAM expression on PBPC correlated with a statistically significant improved (p=0.05) and worsened RFS (p=0.06) respectively. These data confirm the activity of MAM as a negative prognostic factor and show for the first time that MAS could work as a tumor suppressor gene even in a clinical setting, since it protects from recurrence.

Original languageEnglish
Pages (from-to)955-962
Number of pages8
JournalInternational Journal of Oncology
Volume30
Issue number4
Publication statusPublished - Apr 2007

Fingerprint

Neoplasm Micrometastasis
Reverse Transcriptase Polymerase Chain Reaction
Bone Marrow
Breast Neoplasms
Keratins
Gene Expression
Polymerase Chain Reaction
Neoplasms
Immunohistochemistry
Leukapheresis
Blood Component Removal
Tumor Suppressor Genes
SERPIN-B5
Recurrence
Drug Therapy
Survival
Incidence

Keywords

  • Bone marrow
  • Breast cancer
  • Cytokeratins
  • Maspin
  • Micrometastases
  • Peripheral blood progenitor cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer. / Ferrucci, Pier Francesco; Rabascio, C.; Gigli, F.; Corsini, C.; Giordano, G.; Bertolini, F.; Martinelli, G.

In: International Journal of Oncology, Vol. 30, No. 4, 04.2007, p. 955-962.

Research output: Contribution to journalArticle

@article{faf6f2ca553a416ab41810e5b6c32803,
title = "A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer",
abstract = "The incidence and prognostic relevance of bone marrow (BM) and leukapheresis (PBPC) tumor cell contamination (TCC) in breast cancer patients is still to be circumstantiated. We developed a new comprehensive gene expression panel to study cytokeratins (CK), maspin (MAS) and mammaglobin (MAM) as possible predictors of prognosis. Forty-eight patients undergoing high dose chemotherapy (HDCT) and PBPC support were enrolled and analyzed for TCC on 116 PBPC apheresis and 96 BM obtained at basal conditions. All of the patients were evaluated by reverse transcriptase nested PCR (RT-PCR) for MAM and MAS gene expression and by immunocytochemistry (ICC) and nested RT-PCR to evaluate CK expression. PBPC and BM frequency of CK-positive (+) cells was 12-13{\%} by ICC and 71-73{\%} by RT-PCR respectively. Sixty-seven percent of CK ICC + samples were MAM RT-PCR + and 89{\%} of them were MAS RT-PCR +. PBPC and BM frequency of MAM + cells was 21{\%} and 31{\%} respectively, while for MAS + cells it was 48{\%} and 52{\%} respectively by RT-PCR. After 71 mo median FU, 16 patients (33{\%}) relapsed and 14 (88{\%}) had BM/PBPC TCC. No marker had an impact on overall survival (OS) but MAS expression on BM and MAM expression on PBPC correlated with a statistically significant improved (p=0.05) and worsened RFS (p=0.06) respectively. These data confirm the activity of MAM as a negative prognostic factor and show for the first time that MAS could work as a tumor suppressor gene even in a clinical setting, since it protects from recurrence.",
keywords = "Bone marrow, Breast cancer, Cytokeratins, Maspin, Micrometastases, Peripheral blood progenitor cells",
author = "Ferrucci, {Pier Francesco} and C. Rabascio and F. Gigli and C. Corsini and G. Giordano and F. Bertolini and G. Martinelli",
year = "2007",
month = "4",
language = "English",
volume = "30",
pages = "955--962",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer

AU - Ferrucci, Pier Francesco

AU - Rabascio, C.

AU - Gigli, F.

AU - Corsini, C.

AU - Giordano, G.

AU - Bertolini, F.

AU - Martinelli, G.

PY - 2007/4

Y1 - 2007/4

N2 - The incidence and prognostic relevance of bone marrow (BM) and leukapheresis (PBPC) tumor cell contamination (TCC) in breast cancer patients is still to be circumstantiated. We developed a new comprehensive gene expression panel to study cytokeratins (CK), maspin (MAS) and mammaglobin (MAM) as possible predictors of prognosis. Forty-eight patients undergoing high dose chemotherapy (HDCT) and PBPC support were enrolled and analyzed for TCC on 116 PBPC apheresis and 96 BM obtained at basal conditions. All of the patients were evaluated by reverse transcriptase nested PCR (RT-PCR) for MAM and MAS gene expression and by immunocytochemistry (ICC) and nested RT-PCR to evaluate CK expression. PBPC and BM frequency of CK-positive (+) cells was 12-13% by ICC and 71-73% by RT-PCR respectively. Sixty-seven percent of CK ICC + samples were MAM RT-PCR + and 89% of them were MAS RT-PCR +. PBPC and BM frequency of MAM + cells was 21% and 31% respectively, while for MAS + cells it was 48% and 52% respectively by RT-PCR. After 71 mo median FU, 16 patients (33%) relapsed and 14 (88%) had BM/PBPC TCC. No marker had an impact on overall survival (OS) but MAS expression on BM and MAM expression on PBPC correlated with a statistically significant improved (p=0.05) and worsened RFS (p=0.06) respectively. These data confirm the activity of MAM as a negative prognostic factor and show for the first time that MAS could work as a tumor suppressor gene even in a clinical setting, since it protects from recurrence.

AB - The incidence and prognostic relevance of bone marrow (BM) and leukapheresis (PBPC) tumor cell contamination (TCC) in breast cancer patients is still to be circumstantiated. We developed a new comprehensive gene expression panel to study cytokeratins (CK), maspin (MAS) and mammaglobin (MAM) as possible predictors of prognosis. Forty-eight patients undergoing high dose chemotherapy (HDCT) and PBPC support were enrolled and analyzed for TCC on 116 PBPC apheresis and 96 BM obtained at basal conditions. All of the patients were evaluated by reverse transcriptase nested PCR (RT-PCR) for MAM and MAS gene expression and by immunocytochemistry (ICC) and nested RT-PCR to evaluate CK expression. PBPC and BM frequency of CK-positive (+) cells was 12-13% by ICC and 71-73% by RT-PCR respectively. Sixty-seven percent of CK ICC + samples were MAM RT-PCR + and 89% of them were MAS RT-PCR +. PBPC and BM frequency of MAM + cells was 21% and 31% respectively, while for MAS + cells it was 48% and 52% respectively by RT-PCR. After 71 mo median FU, 16 patients (33%) relapsed and 14 (88%) had BM/PBPC TCC. No marker had an impact on overall survival (OS) but MAS expression on BM and MAM expression on PBPC correlated with a statistically significant improved (p=0.05) and worsened RFS (p=0.06) respectively. These data confirm the activity of MAM as a negative prognostic factor and show for the first time that MAS could work as a tumor suppressor gene even in a clinical setting, since it protects from recurrence.

KW - Bone marrow

KW - Breast cancer

KW - Cytokeratins

KW - Maspin

KW - Micrometastases

KW - Peripheral blood progenitor cells

UR - http://www.scopus.com/inward/record.url?scp=34247871453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247871453&partnerID=8YFLogxK

M3 - Article

C2 - 17332935

AN - SCOPUS:34247871453

VL - 30

SP - 955

EP - 962

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -